355 related articles for article (PubMed ID: 15995325)
1. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
2. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
3. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
Bain BJ
Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
[TBL] [Abstract][Full Text] [Related]
4. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
5. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
6. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
7. Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
Pardanani A
Acta Haematol; 2005; 114(1):41-51. PubMed ID: 15995324
[TBL] [Abstract][Full Text] [Related]
8. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
9. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
10. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
11. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
[TBL] [Abstract][Full Text] [Related]
12. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
Gotlib J
Acta Haematol; 2005; 114(1):7-25. PubMed ID: 15995322
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
16. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
17. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
Yamada Y; Rothenberg ME; Lee AW; Akei HS; Brandt EB; Williams DA; Cancelas JA
Blood; 2006 May; 107(10):4071-9. PubMed ID: 16418325
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy.
Gotlib J; Cross NC; Gilliland DG
Best Pract Res Clin Haematol; 2006; 19(3):535-69. PubMed ID: 16781488
[TBL] [Abstract][Full Text] [Related]
19. FIP1L1/PDGFR alpha-associated systemic mastocytosis.
Yamada Y; Cancelas JA
Int Arch Allergy Immunol; 2010; 152 Suppl 1(Suppl 1):101-5. PubMed ID: 20523072
[TBL] [Abstract][Full Text] [Related]
20. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
Tefferi A; Pardanani A
Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
